Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.33 is 12% below its 5-year average of -0.29, around the middle of its 5-year range (-0.42–-0.18).
18.52% above its 12-month average of -0.41.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.08.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
EARNINGS PER SHARE (EPS)
-0.33
EARNINGS PER SHARE (EPS) AVG TTM
-0.41
EARNINGS PER SHARE (EPS) AVG 3Y
-0.34
EARNINGS PER SHARE (EPS) AVG 5Y
-0.29
EARNINGS PER SHARE (EPS) AVG 10Y
-0.23
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+18.52%
CURRENT VS 3Y AVG
+3.65%
CURRENT VS 5Y AVG
-11.86%
CURRENT VS 10Y AVG
-44.44%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
MaxCyte, Inc.
Market Cap
$113.55M
Earnings Per Share (EPS)
-0.33
TTM Avg
-0.41
3Y Avg
-0.34
5Y Avg
-0.29
Market Cap
$113.02M
Earnings Per Share (EPS)
-0.99
TTM Avg
-1.38
3Y Avg
-1.93
5Y Avg
-2.07
Market Cap
$113.02M
Earnings Per Share (EPS)
-1.52
TTM Avg
-3.16
3Y Avg
-3.35
5Y Avg
-6.72
Market Cap
$111.61M
Earnings Per Share (EPS)
-3.21
TTM Avg
-1.79
3Y Avg
-1.14
5Y Avg
-1.14
Market Cap
$115.57M
Earnings Per Share (EPS)
-0.47
TTM Avg
-0.87
3Y Avg
-1.14
5Y Avg
-0.92
Market Cap
$110.12M
Earnings Per Share (EPS)
-0.21
TTM Avg
-0.47
3Y Avg
-0.54
5Y Avg
-0.49
Market Cap
$116.14M
Earnings Per Share (EPS)
-0.89
TTM Avg
-0.91
3Y Avg
-0.79
5Y Avg
-0.74
Market Cap
$116.04M
Earnings Per Share (EPS)
-1.08
TTM Avg
-1.62
3Y Avg
-1.56
5Y Avg
-1.43
Market Cap
$116.47M
Earnings Per Share (EPS)
N/A
TTM Avg
-5.70
3Y Avg
-9.83
5Y Avg
-0.70
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MaxCyte, Inc. (MXCT) | $113.55M | -0.33 | -0.41 | -0.34 | -0.29 |
| Foghorn Therapeutics Inc. (FHTX)vs › | $113.02M | -0.99 | -1.38 | -1.93 | -2.07 |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $113.02M | -1.52 | -3.16 | -3.35 | -6.72 |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $111.61M | -3.21 | -1.79 | -1.14 | -1.14 |
| Lucid Diagnostics Inc. (LUCD)vs › | $115.57M | -0.47 | -0.87 | -1.14 | -0.92 |
| Apyx Medical Corporation (APYX)vs › | $110.12M | -0.21 | -0.47 | -0.54 | -0.49 |
| Genelux Corporation (GNLX)vs › | $116.14M | -0.89 | -0.91 | -0.79 | -0.74 |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.04M | -1.08 | -1.62 | -1.56 | -1.43 |
| BGM Group Ltd. (BGM)vs › | $116.47M | N/A | -5.70 | -9.83 | -0.70 |
| LENZ Therapeutics, Inc. (LENZ)vs › | $116.95M | -4.09 | -2.59 | -6.03 | -6.97 |
Trailing EPS (TTM)
$-0.33
Forward EPS (Est.)
$-0.28
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.42 |
| 2024-12-31 | -0.39 |
| 2023-12-31 | -0.37 |
| 2022-12-31 | -0.19 |
| 2021-12-31 | -0.22 |
| 2020-12-31 | -0.18 |
| 2019-12-31 | -0.24 |
| 2018-12-31 | -0.17 |
| 2017-12-31 | -0.20 |
| 2016-12-31 | -0.10 |
| 2015-12-31 | -0.03 |
| 2014-12-31 | -1.59 |
| 2013-12-31 | -0.02 |
| 2012-12-31 | -0.05 |
